← FDA DRUG APPROVALS

FDA ANDA · ANDA200183

SUMATRIPTAN

Sponsor: HIKMA

APPLICATION
ANDA200183
TYPE
ANDA
ORIGINAL APPROVAL
2013-09-16
LATEST ACTION
2024-12-12
ROUTE
SUBCUTANEOUS
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

SUMATRIPTAN SUCCINATEPrescription
SUMATRIPTAN SUCCINATE EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) · INJECTABLE · SUBCUTANEOUS

Approval history

2024-12-12Labeling · Supplement 2 · standardAP
2024-12-12Labeling · Supplement 1 · standardAP
2013-09-16Not Applicable · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →